

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P1025PC00	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/ES2004/000572	International filing date (day/month/year) 21.12.2004	Priority date (day/month/year) 22.12.2003
International Patent Classification (IPC) or both national classification and IPC C07C215/54		
Applicant RAGACTIVES, S.L. et al.		



- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 5 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

 These annexes consist of a total of 4 sheets.

- This report contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 21.10.2005	Date of completion of this report 06.02.2006
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Breimaier, W Telephone No. +49 89 2399-8327 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/ES2004/000572

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-18 as published

Claims, Numbers

1-14 received on 25.10.2005 with letter of 21.10.2005

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/ES2004/000572

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-14
	No: Claims	
Inventive step (IS)	Yes: Claims	1-14
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-14
	No: Claims	

2. Citations and explanations

see separate sheet

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D1 : Organic Process Research & Development, 2002, vol. 6, pp. 379-383

D2 : US-A 5382600

D3 : WO 01/49649

D4 : WO 98/29402 (ES 2186018)

novelty (Art. 33(2) PCT)

The subject-matter according to claims 1 to 14 is novel.

The present application according to claims 1 to 11 concerns a method for making known tolterodine of formula (I) which mainly differs from the available state of the art processes that the hydroxyl-protected aldehyde of formula (II) rather than the free aldehyde (see D1, scheme 1, 3a; D3, claims 1-4; D4, examples 2 and 3) is used. The intermediates (II) and (III), in particular, (II) according to claims 12 and 13 differs from D1 in the protective moiety "R" (cf scheme 2, 3b) and the hydrobromide salt of the propylamine (III) according to claim 14 is not explicitly mentioned in D2 (cf column 2, lines 32-37 and column 14, lines 2-3).

inventive step (Art. 33(3) PCT)

The subject-matter according to claims 1 to 14 is inventive.

In view of the closest state of the art D1 wherein the free aldehyde 3a which is made by the rhodium catalysed hydroformylation of the phenylethene 2a is subjected to reductive amination furnishing tolterodine in an overall yield up to 60% (see scheme 1 and table 1), the problem posed is the provision of an alternative method for making tolterodine (I) in good yields.

This is solved by subjecting the hydroxyl-protected aldehyde (II) which is obtainable by oxidation of the hydroxyl-protected alcohol (IV) to reductive amination furnishing the hydroxyl-protected diisopropylamine (III) (see examples 4 and 5).

In the known processes the free aldehyde is subjected to reductive amination. Thus, the skilled person would not have been motivated to the use of the hydroxyl-protected reactants requiring additional protection-deprotection steps. Surprisingly, tolteridone is obtained in an easy manner and in good yields.

The intermediates (II) and (III) are inventive in view of the overall inventive process.

further remarks

- Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 and D4 is not mentioned in the description, nor are these documents identified therein.
- The description is not exactly adapted to the claims.

EPO - DG 1

25. 10. 2005

(46)

1


Preliminary Examination must be carried out on the basis of these claims

CLAIMS

(AMENDMENTS UNDER Art. 34 PC

1. A process for obtaining 3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropylamine of formula (I)

5




(I)

wherein the asterisk indicates an asymmetric carbon atom,
its enantiomers or mixtures thereof, or its pharmaceutically acceptable salts,

10

comprising:

(a) oxidizing the alcohol of formula (IV)




(IV)

15

wherein the asterisk has the previously indicated meaning and R is a hydroxyl
protecting group,
to give a compound of formula (II)

2




(II)

wherein R and the asterisk have the previously indicated meanings;

5

(b) reacting the compound of formula (II) with diisopropylamine in the presence of a reducing agent to give a compound of formula (III)



(III)

10

wherein R and the asterisk have the previously indicated meanings;

(c) removing the hydroxyl protecting group from the compound of formula (III) to obtain the compound of formula (I); and

15

(d) if so desired, separating the desired (R) or (S) enantiomer, or the mixture of enantiomers, and/or converting the compound of formula (I) into a pharmaceutically acceptable salt thereof.

20

2. A process according to claim 1, wherein said reducing agent is selected from NaBCNH_3 , $\text{NaB}(\text{AcO})_3\text{H}$ and hydrogen in the presence of Pd/C .

3. A process according to claim 1, wherein the reaction of the compound of formula (II) with diisopropylamine is carried out in a solvent selected from tetrahydrofuran, dichloromethane, acetonitrile and methanol.

5 4. A process according to claim 1, further comprising converting said compound of formula (III) into a salt, and, if desired, isolating said salt from the compound of formula (III) before removing the hydroxyl protecting group [step (c)].

5. A process according to claim 4, wherein said salt of the compound of formula
10 (III) is an inorganic acid addition salt, preferably the hydrochloride, hydrobromide or sulfate of the compound of formula (III).

6. A process according to claim 4 or 5, wherein said salt of the compound of formula (III) is N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropylamine
15 hydrobromide.

7. A process according to claim 1 or 4, wherein the removal of the hydroxyl protecting group from the compound of formula (III), or from said salt of the compound of formula (III), is carried out by means of treating with a mineral acid, a Lewis acid or
20 an organic sulfide.

8. A process according to claim 7, wherein the removal of the hydroxyl protecting group from the compound of formula (III), or from said salt of the compound of formula (III), is carried out by means of treating with aqueous hydrobromic acid in
25 acetic acid.

9. A process according to claim 1, wherein the obtained compound of formula (I) is selected from the (R) enantiomer, the (S) enantiomer and their mixtures.


30 10. A process according to claim 1, wherein the separation of the (R) or (S) enantiomers from the compound of formula (I) is carried out by means of fractional crystallization of the salts of said enantiomers with chiral acids.

4

11. A process according to claim 1, wherein the oxidation of the alcohol of formula (IV) to obtain the aldehyde of formula (II) is carried out using pyridinium chlorochromate (PCC), SO_3 .pyridine (SO_3 .pyr), the 2,2,6,6-tetramethylpiperidine (TMPP) N-oxide/ NaClO system, or the Swern method.

5

12. A compound of formula (II)



10 wherein

R is a C_1 - C_4 alkyl group, an optionally substituted benzyl group, aralkyl, silyl ether, carbonate or benzyl ester; and
the asterisk indicates an asymmetric carbon atom.

15

13. A compound according to claim 12, wherein R is methyl.

14. N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropylamine hydrobromide.